Over 100 Total Lots Up For Auction at Two Locations - WA 11/05, PA 11/06

Penn Medicine and IBA present third annual course on proton therapy

Press releases may be edited for formatting or style | November 02, 2016 Rad Oncology Proton Therapy

Target audiences for the course are: radiation oncology physicians, physicists, and administrators who are interested in learning about proton therapy. At the end of this educational activity, participants should be able to:

Understand the logistics of establishing a proton therapy center with clinical and research capabilities
Describe the current clinical indications and applications for proton therapy
Comprehend the various technical considerations in proton therapy planning
Explain the regulatory aspects of proton therapy planning and delivery from the standpoints of quality assurance and compliance
Better perform their specific roles within the proton therapy center

Details:
When: Friday, November 18, 2016 - Sunday, November 20, 2016
Where: Philadelphia, PA, USA
For more information on registration and other course details, please visit our website at https://protontherapycourse.cvent.com or contact us at courses@protontherapyeducation.com with any questions.

More testimonials of the attendees of the course can be found HERE.


About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1,400 people worldwide, IBA has installed systems across the world. IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

More information can be found at: www.iba-worldwide.com.


About OncoLink
OncoLink was the first online cancer information site, started in 1994, and remains one of the largest. This award-winning site is maintained by a group of oncology healthcare professionals who understand the need of patients, caregivers and healthcare professionals. OncoLink’s content is continually updated and ranges from treatment and disease information for a newly diagnosed patient, support through the side effects of treatment, and into survivorship. OncoLink provides tools and educational materials to support the practice of busy practitioners.

You Must Be Logged In To Post A Comment